WO1999035248A3 - Method of refolding angiostatin - Google Patents

Method of refolding angiostatin Download PDF

Info

Publication number
WO1999035248A3
WO1999035248A3 PCT/US1999/000048 US9900048W WO9935248A3 WO 1999035248 A3 WO1999035248 A3 WO 1999035248A3 US 9900048 W US9900048 W US 9900048W WO 9935248 A3 WO9935248 A3 WO 9935248A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiostatin
refolding
disclosed
subfragments
solubilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/000048
Other languages
French (fr)
Other versions
WO1999035248A2 (en
Inventor
Bernard N Violand
Joseph O Polazzi
Gerald F Casperson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to DK99901279T priority Critical patent/DK1047771T3/en
Priority to AT99901279T priority patent/ATE238414T1/en
Priority to AU21015/99A priority patent/AU2101599A/en
Priority to DE69907139T priority patent/DE69907139T2/en
Priority to EP99901279A priority patent/EP1047771B1/en
Publication of WO1999035248A2 publication Critical patent/WO1999035248A2/en
Publication of WO1999035248A3 publication Critical patent/WO1999035248A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

An efficient method for expressing, solubilizing, refolding, and purifying, angiostatin from inclusion bodies expressed in bacteria is disclosed. Nucleic acids encoding full-length angiostatin and subfragments encoding kringle domains (K1-4, K2-3, K2-4, K1-3, and K1) are also disclosed.
PCT/US1999/000048 1998-01-12 1999-01-11 Method of refolding angiostatin Ceased WO1999035248A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK99901279T DK1047771T3 (en) 1998-01-12 1999-01-11 Method of refolding angiostatin
AT99901279T ATE238414T1 (en) 1998-01-12 1999-01-11 METHOD FOR ANGIOSTATIN REFOLDING
AU21015/99A AU2101599A (en) 1998-01-12 1999-01-11 Method of refolding angiostatin
DE69907139T DE69907139T2 (en) 1998-01-12 1999-01-11 ANGIOSTATIN REFOLDING METHOD
EP99901279A EP1047771B1 (en) 1998-01-12 1999-01-11 Method of refolding angiostatin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7124798P 1998-01-12 1998-01-12
US60/071,247 1998-01-12

Publications (2)

Publication Number Publication Date
WO1999035248A2 WO1999035248A2 (en) 1999-07-15
WO1999035248A3 true WO1999035248A3 (en) 1999-11-11

Family

ID=22100170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000048 Ceased WO1999035248A2 (en) 1998-01-12 1999-01-11 Method of refolding angiostatin

Country Status (8)

Country Link
EP (1) EP1047771B1 (en)
AT (1) ATE238414T1 (en)
AU (1) AU2101599A (en)
DE (1) DE69907139T2 (en)
DK (1) DK1047771T3 (en)
ES (1) ES2198879T3 (en)
PT (1) PT1047771E (en)
WO (1) WO1999035248A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140729A0 (en) * 1998-07-14 2002-02-10 Bristol Myers Squibb Co Lysine binding fragments of angiostatin, pharmaceutical compositions containing the same and processes for the preparation thereof
EP1218495A2 (en) * 1999-12-03 2002-07-03 EntreMed, Inc. METHOD OF PRODUCING AND PURIFYING ANGIOSTATIN$m(3) PROTEIN
US6723536B2 (en) 1999-12-03 2004-04-20 Entremed, Inc. Method of producing and purifying angiostatin
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
US20100144622A1 (en) * 2006-09-29 2010-06-10 Xinli Lin Methods for production of recombinant plasminogen and plasmin polypeptides
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0523296A1 (en) * 1991-07-15 1993-01-20 Eli Lilly And Company An improved method for folding tissue plasminogen activators and derivatives thereof
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0523296A1 (en) * 1991-07-15 1993-01-20 Eli Lilly And Company An improved method for folding tissue plasminogen activators and derivatives thereof
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERNHARD FISCHER ET AL.: "Isolation, renaturation, and formation of disulfide bonds of eukaryotic proteins expressed in Escherichia coli as inclusion bodies", BIOTECHNOLOGY AND BIOENGINEERING INCLUDING: SYMPOSIUM BIOTECHNOLOGY IN ENERGY PRODUCTION AND CONSERVATION., vol. 41, no. 1, 5 January 1993 (1993-01-05), NEW YORK US, pages 3 - 13, XP000605146 *
SCOTT CLEARY ET AL.: "Purification and characterization of tissue plasminogen activator kringle-2 domain expressed in Escherichia coli", BIOCHEMISTRY, vol. 28, no. 4, 21 February 1989 (1989-02-21), EASTON, PA US, pages 1884 - 1891, XP002101498 *
YIHAI CAO ET AL.: "Kringle domains of human angiostatin", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 46, 15 November 1996 (1996-11-15), MD US, pages 29461 - 29467, XP002086445 *

Also Published As

Publication number Publication date
PT1047771E (en) 2003-08-29
DE69907139D1 (en) 2003-05-28
AU2101599A (en) 1999-07-26
EP1047771A2 (en) 2000-11-02
WO1999035248A2 (en) 1999-07-15
ES2198879T3 (en) 2004-02-01
DK1047771T3 (en) 2003-08-11
ATE238414T1 (en) 2003-05-15
DE69907139T2 (en) 2004-01-29
EP1047771B1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
Bulleid et al. Cell-free synthesis of enzymically active tissue-type plasminogen activator. Protein folding determines the extent of N-linked glycosylation
US5225537A (en) Methods for producing hybrid phospholipid-binding proteins
Matsubara et al. Purification and characterization of a fibrinolytic enzyme and identification of fibrinogen clotting enzyme in a marine green alga, Codium divaricatum
WO1999016871A3 (en) Nucleic acid catalysts with endonuclease activity
CA2291892A1 (en) Angiostatin fragments and method of use
WO2000011033A3 (en) Expression and export of angiostatin and endostatin as immunofusins
Argenta et al. Hydrolysis of whey lactose: Kluyveromyces lactis β-galactosidase immobilisation and integrated process hydrolysis-ultrafiltration
AU6380001A (en) Porous ferro- or ferrimagnetic glass particles for isolating molecules
WO2003016492A3 (en) Adamts13 genes and proteins and variants, and uses thereof
WO1999035248A3 (en) Method of refolding angiostatin
DE59107265D1 (en) Enzymatic process for the reduction of oxo compounds, in particular acetophenone and an enzyme suitable therefor
DE69905794D1 (en) Sour protein drinks and methods of making them
AU4597599A (en) Device and method for the determination of protein domain boundaries
DE69534252D1 (en) ENZYMES FOR CLAIMING THE ANCHORAGE REGION OF SURFACE PROTEINS FROM GRAM-POSITIVE BACTERIA
NO20005198D0 (en) Process for separation of magnetic particles mixed in fluid, as well as separation system and separator
AU7951798A (en) Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
WO2001036604A3 (en) Nucleic acids encoding endotheliases, endotheliases and uses thereof
WO1999013085A3 (en) MICROBIAL GENES FOR SECRETED β-GLUCURONIDASES, GENE PRODUCTS AND USES THEREOF
HUP9900505A3 (en) Method of purifying thrombin-like protease enzymes obtained from snake venom
AU4445100A (en) Kringle domains of plasminogen, capable of modulating angiogenesis in vivo
AU5178698A (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses hereof
Matsuo et al. Characterization of plasminogen activator produced by an established cell line from human ovary
WO2000044391A3 (en) Plasminogen kringle 4 region fragments and methods of use
Bakker et al. The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator
Vartio Gelatin‐degrading activity secreted by cultured macrophages from human blood

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999901279

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999901279

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999901279

Country of ref document: EP